Ongoing investigations using IFN-α2b include combination therapy with radiation and autologous dendritic cell vaccines for unresectable or treatment-resistant advanced melanoma (NCT01973322), in combination therapy with tumor-infiltrating lymphocytes (TIL) and nivolumab (NCT03638375), and in comparative studies investigating relative efficacies of various adjuvant therapies (NCT03178123, NCT02506153). The gene discussed is IFNA2; the disease is melanoma.